Eczema treatments: Experimental drug lebrikizumab provides 'rapid' relief to people with severe symptoms, Eli Lilly says

Lebrikizumab, an experimental eczema drug, significantly improved dry skin and itchiness among people with moderate-to-severe symptoms of the skin disease, the Eli Lilly Company said. The monoclonal antibody therapy has been fast-tracked by the FDA.

Related Keywords

New York , United States , Emma Guttman Yassky , Eli Lilly , Ichan School Of Medicine At Mount Sinai , Eli Lilly Company , Drug Administration , Ichan School , Mount Sinai , Lotus Mallbris ,